Intracameral phenylephrine/ketorolac superior to intracamera
Efforts to improve the performance and outcomes of cataract surgery continue, and surgeons have taken another step forward in that regard.The addition of intracameral phenylephrine/ketorolac to the surgical regimen is known to maintain pupillary dilation.

In addition, investigators also found the drug combination of phenylephrine 1.0% and ketorolac 0.3% (Omidria, Omeros Corp.) was superior to intracameral epinephrine by decreasing the rates of intraocular complications, the necessity for using pupillary dilation devices during cataract surgery, the length of the surgery, and best-corrected visual acuity (BCVA) outcomes.The agent is the first combination drug administered intracamerally to receive FDA approval for routine use during cataract surgery.

When the intracameral combination of phenylephrine and ketorolac was being evaluated, the FDA trials showed significant improvements in the drug’s ability to maintain pupillary mydriasis and reductions in postoperative pain. All trial patients received preoperative topical mydriatics and analgesics, no preoperative nonsteroidal anti-inflammatory drugs (NSAIDs) or intracameral epinephrine were administered in the experimental and control groups. Patients with risk factors for pupillary constriction, such as intraoperative floppy iris syndrome (IFIS) and pseudoexfoliation, were excluded from the FDA trials.

Read more at : http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/news/intracameral-phenylephrineketorolac-superior-intracameral-epinephrine?page=0,0
Like
Comment
Share